drugset / Trial / NCT01816789
Age Versus Ovarian Reserve Markers Based Therapy in IVF (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles
RandomizedParallel-groupDouble-blindTreatment
Summary
This randomized controlled trial has been designed for carrying out a comparison of new AMH (Anti-Müllerian Hormone)-based individualized treatment (using a nomogram) with the wide accepted age-based strategy. The main objective of the trial is to assess whether an individualized FSH starting dose can increase the rate of women with an adequate ovarian response in terms of retrieved oocytes (optimal number of retrieved oocytes: 8-14).
Timeline
- Start
- 2013-03
- Primary completion
- 2016-07
- Completion
- 2016-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recombinant human follicle stimulating hormone (r-hFSH) | Protein / enzyme biologic | 150 iu | — |
| Subject | Recombinant human follicle stimulating hormone (r-hFSH) | Protein / enzyme biologic | 225 iu | — |
| Background | buserelin | Unknown | 0.1 ml | Subcutaneous |
Indications
No indication recorded.